IPierian joins Adimab as second public minority investment by search group's corporate venturing division.

Google Ventures, the corporate venturing division of US-listed search group Google, has made its second disclosed investment in a healthcare company.

Google Ventures led the $22m series B round in US-based iPierian, having previously publicly disclosed an investment in Adimab, a yeast-based antibody platform for drug discovery.

The other new investors in the series B round are Japan-based bank Mitsubishi UFJ Capital and ATEL Ventures, the venture capital division of US leasing finance company ATEL Capital Group.

IPierian uses stem…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?